Slide 1: Q1 2025 Results
Q1 2025 Results Investor Relations Presentation
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Aptar is a Global Leader in Drug and Consumer Product Dosing, Dispensing and Protection Technologies
Aptar is a Global Leader in Drug and Consumer Product Dosing, Dispensing and Protection Technologies 2024 % of Total Reported Sales We combine product design, engineering and science to create core differentiating technologies. Food Beverage 4% 67% Proprietary drug delivery systems provide a competi
Slide 4: Global Presence and Customer Base
Global Presence and Customer Base Q1 2025 Net Sales by Ship To Destination EMEA 49% Asia North America 11% 32% Latin America 8% Significant history and global presence enables us to Over 13,000 dedicated employees in build solid and lasting credibility with regional and global 20 countries powerhous
Slide 5: Technology, Innovation and Sustainability Leader
Technology, Innovation and Sustainability Leader Trusted Partner with Sustainability is a Technology and Deep End-User and Growth Driver and Innovation Leader Regulatory Expertise Competitive Advantage 1: APF FuturityTM compared to conventional APF solution. Based on a simplified LCA of Raw Material
Slide 6: Technologies and Industrial Capabilities Deployed Across End Markets
Technologies and Industrial Capabilities Deployed Across End Markets Technology Platforms & Industrial Capabilities Pharma Beauty Personal Care Home Care Beverage Food Dispensing Fine Mist Pumps In Place Dispensing Closures Developing Dispensing Lotion Pumps Active Materials Proprietary Technology E
Slide 7: First Quarter 2025 Reported Results
First Quarter 2025 Reported Results Q1 Reported Sales Q1 Reported EPS Q1 Highlights (in millions $) $1,200 $1.40 $1.23 -5% $1.17 $1,000 $915 -3% $1.20 • Aptar Pharma’s positive results were driven by $887 $1.00 continued demand for proprietary drug delivery $800 systems used for emergency medicines
Slide 8: First Quarter 2025 Adj. EPS and Adj. EBITDA
First Quarter 2025 Adj. EPS and Adj. EBITDA Q1 Adjusted EPS Q1 Adjusted EBITDA * * $1.40 $1.22 Adjusting EPS for -2% $1.20 foreign currency $240 (in millions $) $1.20 $1.00 translation and comparable tax $200 $179 3% $183 $0.80 rate, the prior $0.60 year’s comparable $160 $0.40 earnings would $0.20
Slide 9: Outlook
Outlook Outlook Highlights Earnings Per Share • We expect to build on our solid start to the $1.80 year as we head into the second quarter, with $1.60 $1.56 – $1.64 19 to 21% positive contributions from all three segments. $1.37 $1.40 $1.34 Q2 Effective Tax • As a leader in dosing, dispensing and pr
Slide 10: Consolidated Financial Targets
Consolidated Financial Targets 3-Year Metric Average Q1 2025 Long-term Target Core Sales Growth1 5% 0% 4-7% Adj. EBITDA2 / Sales % 20% 21% 21-23% ROIC3 11% 11% 11-13% Dividend Payout Ratio4 35% 38% 30-40% Leverage Ratio ≈ 1X ≈ 1X 1-3X 1 - Excludes acquisitions and currency effects. 2 - Adjusted EBIT
Slide 11: Pharma
Aptar Pharma
Slide 12: The Aptar Pharma Difference
The Aptar Pharma Difference 4,500+ 2023 1,500+ 10-15 yrs Highest number of new product launches Trusted partner of over 1,500 Average time to develop one new Active and pending patents1 since 2018, while adding an equal, risk- customers worldwide medicine from initial discovery through adjusted valu
Slide 13: Pharma Drug Delivery Solutions Portfolio
Aptar Pharma Drug Delivery Solutions Portfolio Unidose (UDS) & Vial Containment Prefilled Syringe Spray Pumps Bidose (BDS) systems Eye Care Droppers Solutions Solutions Metering Valves for Metered Dose Inhalers Orbital and Prohaler Breath Actuated (MDIs) Dry Powder Inhalers Inhalers (BAIs) Airless T
Slide 14: Pharma has Become our Largest Segment
Aptar Pharma has Become our Largest Segment 2014 vs 2024 2014 % of Total Reported Sales 2024 % of Total Reported Sales Proprietary Drug Delivery Proprietary Systems Drug 23% Delivery Systems 33% $2.6B 6% Injectables Beauty and 54% $3.6B in revenue Closures in revenue Beauty and Closures 71% 8% Injec
Slide 15: Pharma – At a Glance
Aptar Pharma – At a Glance Proprietary Drug Delivery Injectable Solutions & Active Material Science SALES BY REGION Systems Components Solutions (Q1 2025 by Ship To Destination) 35% 17% 48% 64% 14% • Allergy • Biologics • Diabetes Care Suggest adding titles on lower left and lower • Pulmonary • Vacc
Slide 16: Global Reach, Trusted Partner, Broad Offerings
Global Reach, Trusted Partner, Broad Offerings FY 2024 % of Pharma Segment Sales Building Blocks for Growth Active Material Science Solutions Proprietary Drug • Proprietary, high value, precision drug delivery Delivery Systems1 franchise that operates in highly regulated markets 11% • We design and
Slide 17: Pharma Q1 2025
Aptar Pharma Q1 2025 17 1 & 2: See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures. 17
Slide 18: Beauty
Aptar Beauty
Slide 19: Beauty – At a Glance
Aptar Beauty – At a Glance SALES BY REGION Fragrance Color Cosmetics (Q1 2025 by Ship To Destination) High quality spray solutions Unique custom capabilities for with unique custom capabilities, Prestige lipsticks and foundations from Masstige to Prestige 19% 17% 61% 64% 7% Suggest adding titles on
Slide 20: Beauty Technology Portfolio
Aptar Beauty Technology Portfolio Fragrance Pumps Spray Pumps Dispensing Pumps Cosmetic Pumps Aerosol Valves, BoV Airless Systems Precision Dispensing & Accessories Custom Lipsticks Refill Devices Sampling & Trial Sizes Turnkey Solutions 20
Slide 21: We Create an Enhanced End-User Experience that Engages the Consumer
We Create an Enhanced End-User Experience that Engages the Consumer FY 2024 % of Beauty Segment Sales Home Care Focused on Profitable Growth Fragrance, Facial Skincare and Color 4% Cosmetics • Refocused “go-to-market” strategies and customer engagement • Improved operations worldwide (footprint, eff
Slide 22: Beauty Q1 2025
Aptar Beauty Q1 2025 22 1 & 2: See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures. 22
Slide 23: Closures
HEINZ \etay to \Gau - — ae
Slide 24: Closures – At a Glance
Aptar Closures – At a Glance SALES BY REGION Food Beverage (Q1 2025 by Ship To Destination) Dispensing closures focused Wide range of solutions for on quality, functionality, functional drinks, bottled 64% 30% water, juices and more 48% 17% 10% convenience and safety Suggest adding titles on lower l
Slide 25: Closures Technology Portfolio
Aptar Closures Technology Portfolio Snap Tops Tube Tops Disc Tops Wide Mouth Snap Tops Directional Dispensing Inverted Tops Pour Spouts Safety Caps Dosing Cap Push Pull Flexible Fitments Sport Caps Concentrates Closures Reuse / Refill Healthcare 25
Slide 26: Global Reach, Trusted Partner, Broad Offerings
Global Reach, Trusted Partner, Broad Offerings FY 2024 % of Closures Segment Sales Competitive Advantages Other1 Food • Broadest geographic footprint, makes us ideal partner for 8% global CPG companies as well as regional players Personal Care • Wide offering of dispensing closures 18% • Innovate lo
Slide 27: Closures Q1 2025
Aptar Closures Q1 2025 27 1 & 2: See accompanying slide titled: Forward Looking Statements & Non-GAAP Financial Measures. 27
Slide 28: Sustainability
Sustainability
Slide 29: Aptar is committed to accelerating our efforts
Memberships / Partnerships Aptar is committed to accelerating our efforts. 29
Slide 30: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage that drives impact for our customers CDP Forbes Newsweek Time Barron’s EcoVadis CDP ISS ESG USA Today Le Point Climate A One of the In the Top 100 One of the In the Top 100 Sustainability Rating Recognized
Slide 31: Innovative Solutions
Innovative Stock Closure Portfolio Solutions Designed to Recycle Mono Material (PCR) Designed to promote a more circular economy Exploring connected Refillable Metal Free Options refillable solutions 31
Slide 32: Leader in Sustainability
Leader in Sustainability 2023 Corporate Sustainability Report* 2024 Report coming soon! Barron’s logo used with permission. ©2025 Dow Jones & Company, Inc. *The 2023 Corporate Sustainability Report is available on our website at https://www.aptar.com/esg/reporting-center/. 32
Slide 33: Employee Safety and Engagement
Employee Safety and Engagement • Environment, Health and Safety Program includes an Ergonomics and Behavior-Based Safety Program • Leaning and development programs are offered in a hybrid format which combines a mixture of different learning methods • In addition to supporting our global organizatio
Slide 34: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 34